EQL Pharma (EQL) CEO Sitdown with Kalqyl Q1 24/25 earnings summary

Sales performance and product launches

• Sales volumes for key antibiotics and penicillin products are at expected long-term levels, with some minor variations by product size or strength.

• Four new pharmacy products were launched in Denmark, with expected marginal sales increases in coming quarters as these products reach full market impact.

• Growth was driven by all markets, with other European countries contributing more than before.

• New hospital product contracts in Denmark and Iceland, and extended agreements in Sweden and Denmark, will mainly impact the next fiscal year.

International expansion and partnerships

• Medice received a temporary 12-month subsidy for Melozan in Germany, supporting initial market entry and brand building among child psychiatrists and related organizations.

• Market development in Germany is expected to take time due to cultural differences in prescribing melatonin to children.

• Adalvo, the partner for markets outside Europe, is exploring opportunities in Latin America, APAC, and MENA, but progress is slow and still in early stages.

Pipeline and business development

• Four new products were added to the pipeline: one development product (3-5 years to market) and three licensed products with varying regulatory timelines.

• Three of the new products are retail pharmacy products, and one is a hospital product.

• A new Specialty Pharma business area is being developed, focusing on highly specialized medicines and requiring new competencies.

• The company is acting as a distributor for three generic companies outside the Nordics, using a scalable, low-capex model.